Skip to main content

Table 7 Overall and progression-free survival of patients treated by nivolumab using cox proportional hazard regression model

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Variable Overall survival Progression-free survival
HR 95% C.I. p value HR 95% C.I. p value
Sex
 male 1    1   
 female 1.196 0.608–2.353 0.604 1.714 0.913–3.220 0.094
Age
  ≤ 66 1    1   
  > 66 1.005 0.565–1.786 0.987 0.8503 0.492–1.470 0.561
ECOG PS
 0 1    1   
  ≥ 1 3.472 1.236–9.753 0.018 1.49 0.698–3.182 0.303
Primary site
 Gastric 1    1   
 Esophagogastric junction 0.8768 0.392–1.963 0.749 0.669 0.301–1.487 0.324
Disease status
 Metastatic 1    1   
 Relapsed 1.241 0.321–4.798 0.755 0.903 0.4899.-1.665 0.744
Histological type
 Intestinal type 1    1   
 Diffuse type 0.881 0.490–1.581 0.67 1.067 0.622–1.833 0.813
Organ with metastasis
 1 1    1   
  ≥ 2 1.656 0.858–3.196 0.133 1.699 0.932–3.097 0.084
Lymph node metastasis
 no 1    1   
 yes 0.995 0.529–1.871 0.987 0.959 0.539–1.707 0.888
Hematogenous metastasis
 no 1    1   
 yes 1.576 0.871–2.853 0.133 1.491 0.860–2.584 0.155
Peritoneal metastasis
 no 1    1   
 yes 1.049 0.591–1.862 0.8701 0.969 0.566–1.659 0.909
Previous treatment regimens
 2 1    1   
  ≥ 3 1.325 0.742–2.367 0.342 1.103 0.636–1.911 0.728
HER-2 status
 no 1    1   
 yes 1.923 0.985–3.754 0.055 1.7 0.886–3.262 0.111
Prior trastuzumab
 no 1    1   
 yes 2.123 1.036–4.352 0.040 1.672 0.844–3.313 0.141
Prior ramucirumab
 no 1    1   
 yes 1.082 0.504–2.319 0.841 1.265 0.616–2.596 0.522
Treatment period before nivolumab
  ≤ 14.9 1    1   
  > 14.9 0.924 0.521–1.639 0.787 0.889 0.520–1.519 0.666
Immune-related adverse events (≥grade 2)
 no 1    1   
 yes 0.3174 0.124–0.815 0.017 0.615 0.298–1.271 0.19
Best overall response
 Non-responder 1    1   
 Responder 0.14 0.065–0.302 < 0.001 0.036 0.011–0.113 < 0.001
Subsequent chemotherapy after nivolumab
 No 1    1   
 Yes 0.31 0.169–0.567 < 0.001 0.596 0.346–1.025 0.061